This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-19. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
==== Sulfur ==== The original sulfur isotopic reference material was the Canyon Diablo Troilite (CDT), a meteorite recovered from Meteor Crater in Arizona. The Canyon Diablo Meteorite was chosen because it was thought to have a sulfur isotopic composition similar to the bulk Earth. However, the meteorite was later found to be isotopically heterogeneous with variations up to 0.4‰. This isotopic variability resulted in problems for the inter-laboratory calibration of sulfur isotope measurements. A meeting of the IAEA in 1993 defined Vienna Canyon Diablo Troilite (VCDT) in an allusion to the earlier establishment of VSMOW. Like the original SMOW and VPDB, VCDT was never a physical material that could be measured but was still used as the definition of the sulfur isotopic scale. For the purposes of actually measuring 34S/32S ratios, the IAEA defined the δ34S of IAEA-S-1 (originally called IAEA-NZ1) to be -0.30‰ relative to VCDT. These changes to the sulfur isotope reference materials greatly improved inter-laboratory reproducibility.
==== Additional studies ==== Some additional information about giving meloxicam to cats from researchers is as follows: A peer-reviewed journal article cites NSAIDs, including meloxicam, as causing gastrointestinal upset and, at high doses, acute kidney injury and CNS signs such as seizures and comas in cats. It adds that cats have a low tolerance for NSAIDs. Also, in another scientific journal there is talk of research according to which cats that received meloxicam had greater proteinuria at 6 months than cats that received placebo. It was concluded that meloxicam should be used with caution in cats with chronic kidney disease.
== Selected publications == Butler, J et al. "Empagliflozin after Acute Myocardial Infarction." N Engl J Med 2024. Anker SD, Butler J et al. "Empagliflozin in Heart Failure with a Preserved Ejection Fraction." N Engl J Med 2021. Packer M, Butler J et al. "Empagliflozin and Major Renal Outcomes in Heart Failure." N Engl J Med 2021. Butler J et al. "Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials." Lancet 2024. Armstrong PW, Butler J et al. "Effect of Vericiguat vs Placebo on Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial." JAMA 2020. Butler J et al. "Redefining Heart Failure with a Reduced Ejection Fraction." JAMA 2019.
=== Branched polymers === A monomer with functionality of 3 or more will introduce branching in a polymer and will ultimately form a cross-linked macrostructure or network even at low fractional conversion. The point at which a tree-like topology transits to a network is known as the gel point because it is signalled by an abrupt change in viscosity. One of the earliest so-called thermosets is known as Bakelite. It is not always water that is released in step-growth polymerization: in acyclic diene metathesis or ADMET, dienes polymerize with loss of ethene.
The Soviet Zond spacecraft was not yet ready for piloted circumlunar missions in 1968, after six unsuccessful automated test launches: Kosmos 146 on March 10, 1967; Kosmos 154 on April 8, 1967; Zond 1967A on September 28, 1967; Zond 1967B on November 22, 1967; Zond 1968A on April 23, 1968; and Zond 1968B in July 1968. Zond 4 was launched on March 2, 1968, and successfully made a circumlunar flight, but encountered problems with its Earth reentry on March 9, and was ordered destroyed by an explosive charge 15,000 meters (49,000 ft) over the Gulf of Guinea. The Soviet official announcement said that Zond 4 was an automated test flight which ended with its intentional destruction, due to its recovery trajectory positioning it over the Atlantic Ocean instead of over the USSR. During the summer of 1968, the Apollo program hit another snag: the first pilot-rated Lunar Module (LM) was not ready for orbital tests in time for a December 1968 launch. NASA planners overcame this challenge by changing the mission flight order, delaying the first LM flight until March 1969, and sending Apollo 8 into lunar orbit without the LM in December. This mission was in part motivated by intelligence rumors the Soviet Union might be ready for a piloted Zond flight in late 1968. In September 1968, Zond 5 made a circumlunar flight with tortoises on board and returned safely to Earth, accomplishing the first successful water landing of the Soviet space program in the Indian Ocean.
Sources: en.wikipedia.org
Pakistan operates as a democratic parliamentary federal republic, with Islam designated as the state religion. The military's influence in mainstream politics has been significant throughout Pakistan's history. Initially adopting a constitution in 1956, Pakistan saw it suspended by Ayub Khan in 1958, replaced by a second constitution in 1962. Under the leadership of Zulfikar Ali Bhutto, the 1973 constitution established a parliamentary system, but it was suspended under Zia-ul-Haq's martial law in 1977 and restored, with amendments, in 1985. The eras of 1958–1971, 1977–1988, and 1999–2008 witnessed military coups, leading to martial law and military leaders governing de facto as presidents. Presently, Pakistan operates a multi-party parliamentary system, with distinct checks and balances among government branches. The first successful democratic transition occurred in May 2013. Pakistani politics revolves around a blend of socialism, conservatism, and the third way, with the three main political parties being the conservative Pakistan Muslim League (N), socialist Pakistani People's Party, and centrist Pakistan Tehreek-e-Insaf. Constitutional amendments in 2010 curtailed presidential powers, enhancing the role of the prime minister.
Gastric pentadecapeptide BPC-157 (also known as Body Protection Compound 157, bepecin, or PL 14736) is a synthetic fifteen amino acid oligopeptide derived from a protein found in human gastric juice. BPC-157 has been studied primarily in laboratory animals. BPC-157 is not approved by any drug regulatory agency for human use, and there is limited data regarding its effectiveness on humans. The peptide has gained popularity among athletes and the general public for injury recovery, leading the World Anti-Doping Agency to ban it in 2022. Health authorities discourage its use due to insufficient human safety data, and some jurisdictions have restricted it as a prescription-only medicine despite it not being available through legitimate prescriptions. Additionally, because the compound promotes blood vessel formation (angiogenesis), there are theoretical concerns about potential cancer promotion that require further investigation. The peptide was discovered during research on human gastric juice. The amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. BPC-157 is stable at room temperature and bioavailable in rodent models when administered IM or IV. The peptide demonstrates unusual stability in human gastric juice, remaining intact for more than 24 hours.
The physics of FTICR is similar to that of a cyclotron at least in the first approximation. In the simplest idealized form, the relationship between the cyclotron frequency and the mass-to-charge ratio is given by
=== Intraocular viscoelastic injection === It is used as an aid in ophthalmic surgery acting as aqueous and vitreous humor, e.g. in cataract extraction (intra- and extracapsular), intraocular lens implantation, corneal transplant, glaucoma filtration, and retina attachment surgery and in the treatment of dry eyes. In surgical procedures in the anterior segment of eyeball, instillation of sodium hyaluronate its viscoelasticity enables maintenance of a deep chamber during surgical manipulation since the solution does not flow out of the open anterior chamber, allowing for efficient manipulation with less trauma to the corneal endothelium and other surrounding tissues. Its viscoelasticity also helps to push back the vitreous face and prevent formation of a postoperative flat chamber. In posterior segment surgery, sodium hyaluronate serves as a surgical aid to gently separate, maneuver, and hold tissues. It creates a clear field of vision, facilitating intra-operative and post-operative inspection of the retina and photocoagulation.
== Live performances == In October 2008, Heap travelled to America to perform at Pop!Tech in Camden, Maine. She performed the song 'Wait It Out' live, for the first time ever on 24 October. The performance was recorded and released on Youtube.com the following day. On 24 August 2009, Heap appeared on the Late Show with David Letterman (although the episode didn't air until the 28th) and performed "First Train Home". On her Twitter page, Imogen admitted that she messed up on the second line of the second verse during the performance. The following day, on 25 August, Imogen headed to the WNYC Radio Station in New York to play "First Train Home" and "Half Life" on air and give a short interview.
Sources: en.wikipedia.org
== Design == The newer TGI Fridays franchises (as well as redesigned restaurants) are more contemporary, with wallpaper, granite exteriors, and red-and-white striped lamps instead of Tiffany. The exteriors have stucco, the entrance doors have F-shaped handles, and a metal cup above the door has a stripe saying "In Here, It's always Friday". The logo design was evolved in 2013 by Jane MacDowall and her creative team in Scotland. Most TGI Fridays have a propeller and a rowing scull on display as part of their antiques, which are actually a part of a story told to all TGI Fridays employees; the scull always contains a pair of saddle shoes and a bottle of champagne to remind employees of the value of teamwork, leadership, and celebrating success. The propeller is always above or near the bar. The thought is that the bar "propels" the restaurant.
=== Interactions === ERp44 Hisatsune et al. demonstrated, by co-immunoprecipitation, an interaction between ERAP1 and the disulfide-shuffling chaperone ERp44, facilitated by disulfide bonds formed with cysteine residues in the exon 10 loop of ERAP1. This interaction was proposed to be the main mechanism for ER retention.
They were treated for about four years and gained 4-8 cm in adult height. Controversy has arisen as to whether all of these children were truly "short normal" children, since the average IGF1 was low. Approval of HGH for the treatment of this extreme degree of shortness led to an increase in the number of parents seeking its use to make otherwise normal children a little taller.
=== Tenure === On August 12, 2022, Stansbury voted to pass the Inflation Reduction Act of 2022. According to a FiveThirtyEight analysis, during the 117th Congress, she voted with President Joe Biden's stated position 100% of the time. When President Donald Trump entered the House chamber for the 2025 Joint Session of Congress, Stansbury held a sign that said "this is not normal" to protest the mass firing of federal workers.
In 1990, Maroon et al. published the first microsurgical approach to far lateral disc herniations in the lumbar spine and in 2007, they published the case of Golfer's Stroke from Vertebral Artery Dissection. Further groundbreaking publications include the use of fish oil as an anti-inflammatory and alternative to nonsteroidal drugs for discogenic pain (2006); a unifying, immunoexcitotoxicity hypothesis for chronic traumatic encephalopathy (2011); and the possible use of a restricted calorie ketogenic diet for the treatment of glioblastoma multiforme (2013). In 2021, he began collaborating with Dr. Pravat Mandal on research utilizing magnetic resonance spectroscopy to assess glutathione deficiency—the brain's most abundant antioxidant—as a potential biomarker for the early diagnosis of Alzheimer's and Parkinson's diseases. In 2023, he was appointed to the board of directors of Syncromune, a biotechnology company developing novel immunotherapies that integrate cryosurgery and checkpoint inhibitor drugs for the treatment of solid tumors. In 2025, he and his colleagues received a research grant from the Chuck Noll Foundation to investigate glutathione deficiency in the brains of former National Football League (NFL) players and former Navy SEALs. Dr. Maroon is also an advocate for the use of hyperbaric oxygen therapy in the treatment of post-concussion syndrome, post-traumatic stress disorder (PTSD), long COVID, stroke, and spinal cord injury. He has authored several publications on these topics.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.